• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Oculis Reports Q3 2023 Financial Results and Provides Company Update

    11/15/23 6:30:00 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OCS alert in real time by email
    • Reported lead product candidate OCS-01 eye drop met both primary endpoints in Phase 3 OPTIMIZE trial for inflammation and pain after cataract surgery following positive readout of Stage 1 of the Phase 3 DIAMOND trial for diabetic macular edema (DME)
    • Enrolled first patient in the investigator-initiated LEOPARD trial evaluating OCS-01 for treatment of cystoid macular edema (CME)
    • Cash and investments of $116.5 million adequately funded to deliver on key business and clinical milestones

    ZUG, Switzerland and BOSTON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis" or the "Company"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced third quarter financial results for the period ended September 30, 2023, and an overview of the Company's progress.

    Riad Sherif M.D., Chief Executive Officer of Oculis: "In this quarter we advanced on our late stage clinical development programs for our leading assets. Following the two positive readouts for our lead product candidate OCS-01 eye drop, we initiated activities to commence Stage 2 of the Phase 3 DIAMOND 1 & 2 trials for DME and the second Phase 3 trial for inflammation and pain after cataract surgery. The LEOPARD study of OCS-01 in CME enrolled its first patient and enrollment is currently ongoing as planned. In addition, we started preparing for the Phase 2b trial of OCS-02, a novel biologic eye drop, in dry eye disease (DED). We look forward to enrolling the first patients in our planned and ongoing trials and anticipate having multiple readouts and value inflection points in 2024 across our innovative pipeline addressing key areas of high unmet patient need in Ophthalmology."

    Q3 2023 Highlights

    • Advanced Oculis' lead product candidate OCS-01, a novel high concentration preservative-free topical OPTIREACH® formulation of dexamethasone with the potential to treat both front and back of the eye indications:
      • Reported positive topline results from Phase 3 OPTIMIZE trial of once daily OCS-01 for inflammation and pain following ocular surgery (August 2023). The trial met both hierarchical primary endpoints, showing a statistically significant higher percentage of patients with no inflammation at Day 15 and no pain at Day 4 following cataract surgery compared to vehicle.
      • Enrolled the first patient in the investigator-initiated study LEOPARD to evaluate the efficacy and safety profile of OCS-01 eye drops for the treatment of two different forms of CME: uveitic macular edema (UME) and post-surgical macular edema (PSME). This study is sponsored by the Global Ophthalmic Research Center (Los Altos, California) and led by Quan Dong Nguyen, M.D., M.Sc., FAAO, FARVO, FASRS, Professor of Ophthalmology at the Byers Eye Institute, Stanford University School of Medicine with financial support provided by Oculis.
      • Commenced start-up activities for Stage 2 of the Phase 3 DIAMOND trial (DIAMOND-1), the second pivotal Phase 3 trial for DME (DIAMOND-2) and the second Phase 3 trial for the treatment of inflammation and pain following cataract surgery (OPTIMIZE-2). Oculis anticipates first patient enrollment toward the end of 2023 and beginning of 2024 in all three pivotal trials.
    • Commenced start-up activities for Phase 2b trial with OCS-02, a novel eye drop with potential to become the first approved topical anti-TNFα for DED. Oculis is on track to deliver the first patient first visit before the end of 2023 with clinical data readout expected in mid-2024.
    • Strengthened the executive leadership team with the appointment of Rebecca Weil, Ph.D., a seasoned global ophthalmology commercial executive, as Chief Commercial Officer. Ms. Weil is building Oculis' commercial organization readiness plan and preparing for its first potential launch in the U.S. with OCS-01 for the treatment of inflammation and pain following ocular surgery.

    Upcoming Clinical Milestones

    In the fourth quarter of 2023 the Company continues to focus on advancing its innovative pipeline and planned clinical development programs including:

    OCS-01

    • Following the positive readout in Stage 1, initiation of Stage 2 of the Phase 3 DIAMOND trial of OCS-01 for DME is underway. Stage 2 will include a 6-week induction phase, followed by 46-week maintenance phase of OCS-01 vs. vehicle. Consistent with Stage 1, the primary endpoint is change in best corrected visual acuity (BCVA) early treatment diabetic retinopathy study (ETDRS) letter score. Secondary endpoints include percentage of patients with ≥ 3-line gain in BCVA and change in central subfield thickness (CST) as measured by spectral domain optical coherence tomography (SD-OCT). All endpoints will be evaluated at Week 52. The second Phase 3 trial for DME (DIAMOND-2) will follow shortly after.
    • The second Phase 3 OPTIMIZE-2 trial to support the NDA submission is expected to start in the fourth quarter of 2023. Patients in the trial will be treated with once-daily OCS-01 vs. vehicle arm for 2 weeks. Hierarchical primary endpoints are the absence of anterior chamber cells on Day 15 and absence of pain on Day 4.
    • The investigator-initiated study of OCS-01 for the treatment of CME is advancing with all clinical sites activated and patient enrollment on track. Oculis anticipates topline readout in the fourth quarter of 2024.

    OCS-02

    • Phase 2b trial in DED is on track for first patient first visit in the fourth quarter of 2023. The trial will evaluate the safety and efficacy vs. vehicle in signs and symptoms, and further explore whether patients with a certain genotype (i.e., single-nucleotide polymorphism, SNP, related to the TNF receptor) respond better to OCS-02 than all comers. Another Phase 2b trial of OCS-02 for the treatment of uveitis is expected to follow thereafter.

    OCS-05

    • Phase 2a PoC ACUITY trial in France for OCS-05, a potential disease-modifying neuroprotective candidate for acute optic neuritis (AON), is ongoing. The trial evaluates the safety and tolerability of a once-daily injection of OCS-05 vs. placebo for 5 days, in addition to current standard of care and includes a follow-up period of 6 months. A topline readout is expected in the fourth quarter of 2024. Concurrently, the Company is working on IND enabling activities in the U.S.

    Q3 Financial Highlights

    • Cash position: As of September 30, 2023, the Company had total cash, cash equivalents and short-term investments of CHF 106.6 million or $116.5 million, compared to CHF 19.8 million or $21.4 million as of December 31, 2022. The increase in cash position reflects proceeds from financing transactions during the first half of 2023. Based on our current development plans, we expect our cash runway to fund operations into late 2025.
    • Research and development expenses were CHF 8.9 million or $10.0 million for the three-month period ending September 30, 2023, compared to CHF 4.6 million or $4.8 million in the same period in 2022. The increase was primarily due to clinical development activities, including the initiation of the Phase 3 DIAMOND Stage 2 program of OCS-01 in DME.
    • General and administrative expenses were CHF 4.3 million or $4.9 million for the three-month period ending September 30, 2023, compared to CHF 2.5 million or $2.6 million in the same period in 2022. The increase was primarily due to costs related to becoming a public company.
    • Q3 Quarter-to-date net loss was CHF 17.4 million or $19.7 million, or CHF 0.48 or $0.54 loss per share (basic and diluted), for the three-month period ending September 30, 2023, compared to CHF 10.0 million or $10.4 million, or CHF 2.88 or $2.98 loss per share (basic and diluted), in the same period in 2022. The increase in net loss was primarily driven by the increase in clinical development expenses.
    • Q3 Year-to-date net loss was CHF 76.3 million or $84.5 million for the nine months ending September 30, 2023, or CHF 2.76 or $3.06 loss per share (basic and diluted) compared to CHF 29.5 million or $31.0 million, or CHF 8.71 or $9.15 loss per share (basic and diluted) for the nine months ended September 30, 2022. The increase in year-to-date net loss was primarily driven by the increase in clinical development expenses, expenses related to becoming a public company, merger and listing expense and the fair-value (non-cash) adjustment of outstanding warrants.
    • Q3 Year-to-date Non-IFRS net loss was CHF 36.5 million or $40.4 million, or CHF 1.32 or $1.46 loss per share (basic and diluted), for the nine months ended September 30, 2023, compared to CHF 29.5 million or $31.0 million, or CHF 8.71 or $9.15 loss per share (basic and diluted), for the same period in 2022. The increase in non-IFRS net loss was primarily driven by increases in clinical development expenses, expenses related to becoming a public company, and an increase in the fair-value (non-cash) adjustment of outstanding warrants.

    Non-IFRS Financial Information

    This press release contains financial measures that do not comply with International Financial Reporting Standards (IFRS) including non-IFRS year-to-date loss, and non-IFRS loss attributable to equity holders per common share. These non-IFRS financial measures exclude the impact of items that the Company's management believes affect comparability or underlying business trends. These measures supplement the Company's financial results prepared in accordance with IFRS. The Company's management uses these measures to better analyze its financial results and better estimate its financial outlook. In management's opinion, these non-IFRS measures are useful to investors and other users of the Company's financial statements by providing greater transparency into the ongoing operating performance of the Company and its future outlook. Such measures should not be deemed to be an alternative to IFRS requirements.

    The non-IFRS measures for the reported periods reflect adjustments made to exclude:

    • Merger and listing expense, which was a one-time and non-cash expense CHF 34.9 million or $38.2 million in the first quarter of 2023 and in the year-to-date total operating expenses.
    • During the third quarter of 2023, the Company gave effect to the impending dissolution of its Merger Sub 2 entity pursuant to the Business Combination Agreement with EBAC, which is expected to be completed in the coming months. As a result, the cumulative translation adjustments related to Merger Sub 2 previously reported in equity and recognized in other comprehensive loss, were reclassified from equity to the Condensed Consolidated Interim Statement of Loss for the three and nine months ended September 30, 2023. The resulting non-cash foreign exchange impact of such reclassification amounted to CHF 5.0 million or $5.7 million for the three and nine months ended September 30, 2023.

    The non-IFRS measures presented here are also unlikely to be comparable with non-IFRS disclosures released by other companies. See the "Reconciliation of Non-IFRS Measures (Unaudited)" table below for a reconciliation of these non-IFRS measures to the most directly comparable IFRS measures.



    Condensed Consolidated Statements of Financial Position (Unaudited)

    (Amounts in CHF thousands)As of September 30, As of December 31,
     2023 2022
    ASSETS   
        
    Non-current assets   
    Property and equipment, net312 365
    Intangible assets12,206 12,206
    Right-of-use assets798 758
    Other non-current assets129 74
    Total non-current assets13,445 13,403
        
    Current assets   
    Other current assets7,276 2,959
    Accrued income1,625 912
    Short-term financial assets75,871 -
    Cash and cash equivalents30,724 19,786
    Total current assets115,496 23,657
        
    TOTAL ASSETS128,941 37,060
        
    EQUITY AND LIABILITIES   
        
    Shareholders' equity   
    Share capital366 39
    Share premium288,030 10,742
    Reserve for share-based payment5,337 2,771
    Actuarial loss on post-employment benefit obligations (560)  (264)
    Treasury shares-  (1)
    Cumulative translation adjustments (289)  (300)
    Accumulated losses (187,281)  (110,978)
    Total equity105,603  (97,991)
        
    Non-current liabilities   
    Long-term lease liabilities505 491
    Long-term financial debt- 122,449
    Long-term payables377 -
    Defined benefit pension liabilities305 91
    Total non-current liabilities1,187 123,031
        
    Current liabilities   
    Trade payables6,712 3,867
    Accrued expenses and other payables8,680 8,011
    Short-term lease liabilities182 142
    Warrant liabilities6,577 -
    Total current liabilities22,151 12,020
        
    Total liabilities23,338 135,051
        
    TOTAL EQUITY AND LIABILITIES128,941 37,060
        

    Condensed Consolidated Statements of Loss (Unaudited)

            
             
    (Amounts in CHF thousands, except per share data) For the three months ended September 30, For the nine months ended September 30,
      2023 2022 2023 2022
    Grant income 219 202 698 698
    Operating income 219 202 698 698
    Research and development expenses  (8,872)  (4,592)  (21,218)  (15,335)
    General and administrative expenses  (4,306)  (2,483)  (13,147)  (6,626)
    Merger and listing expense - -  (34,863) -
    Operating expenses  (13,178)  (7,075)  (69,228)  (21,961)
             
    Operating loss  (12,959)  (6,873)  (68,530)  (21,263)
             
    Finance income 520 61 773 70
    Finance expense  (11)  (1,834)  (1,303)  (5,119)
    Fair value adjustment on warrant liabilities  (2,434) -  (4,638) -
    Foreign currency exchange gain (loss), net  (2,645)  (1,302)  (2,485)  (3,134)
    Finance result, net  (4,570)  (3,075)  (7,653)  (8,183)
             
    Loss before tax for the period  (17,529)  (9,948)  (76,183)  (29,446)
             
    Income tax benefit (expense) 116  (6)  (120)  (69)
             
    Loss for the period  (17,413)  (9,954)  (76,303)  (29,515)
             
    Loss per share:        
    Basic and diluted loss attributable to equity holders                   (0.48)                   (2.88)                   (2.76)                   (8.71)
             

    Reconciliation of Non-IFRS Measures (Unaudited)

            
            
    (Amounts in CHF thousands, except per share data)       
     For the three months ended September 30, For the nine months ended September 30,
     2023 2022 2023 2022
    IFRS loss for the period (17,413)  (9,954)  (76,303)  (29,515)
    Non-IFRS adjustments:       
    Merger and listing expense (i)- - 34,863 -
    Merger Sub 2 reclassification from equity to foreign exchange loss (ii)4,978 - 4,978 -
    Non-IFRS loss for the period (12,435)  (9,954)  (36,462)  (29,515)
            
    IFRS basic and diluted loss attributable to equity holders                  (0.48)                   (2.88)                   (2.76)                   (8.71)
    Non-IFRS basic and diluted loss attributable to equity holders                 (0.34)                  (2.88)                  (1.32)                  (8.71)
            
    IFRS weighted-average number of shares used to compute loss per share basic and diluted36,330,836 3,461,666 27,673,950 3,387,614
            
    (i) Merger and listing expense is the difference between the fair value of the shares transferred and the fair value of the EBAC net assets per the Business Combination Agreement. This merger and listing expense is non-recurring in nature and represented a share-based payment made in exchange for a listing service and does not lead to any cash outflows.
    (ii) The reclassification of cumulative translation adjustments from equity to foreign exchange loss results from the impact of the impending dissolution of Merger Sub 2, which is expected to occur in the coming months. This exchange loss is non-recurring in nature and does not lead to any cash outflows.
            
            

    About Oculis

    Oculis (NASDAQ:OCS) is a global biopharmaceutical company purposefully driven to save sight and improve eye care. Oculis' highly differentiated clinical-stage pipeline comprises multiple innovative product candidates in development for eye diseases of high unmet need. It includes OCS-01 eye drops, a topical candidate in Phase 3 development for diabetic macular edema (DME) and inflammation and pain following ocular surgery; OCS-02 eye drops, a topical biologic candidate in Phase 2 development for dry eye disease (DED) and uveitis; and OCS-05, a disease-modifying candidate for acute optic neuritis (AON) and other neuro-ophthalmic disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The first in-patient, proof-of-concept trial with OCS-05 is currently ongoing in France. Headquartered in Switzerland and with operations in the US, Oculis' goal is to deliver life-changing eye treatments to patients worldwide. The company is led by an experienced management team with a successful track record in the pharmaceutical industry, supported by leading international healthcare investors.

    For more information, please visit: www.oculis.com

    Oculis Contacts

    Ms. Sylvia Cheung, CFO

    [email protected]

    Investor & Media Relations

    LifeSci Advisors

    Corey Davis, Ph.D.

    [email protected]

    1-212-915-2577

    Cautionary Statement Regarding Forward Looking Statements

    This press release contains forward-looking statements and information. For example, statements regarding the potential benefits of OCS-01, OCS-02 and OCS-05, including patient impact and market opportunity; the potential of OCS-01 for treating front- and back-of-the-eye diseases; the potential for OCS-01 to become a new standard of care with the first once-daily, topical, preservative-free corticosteroid for treating inflammation and pain following ocular surgery; the potential of OCS-01 for the treatment of DME, inflammation and pain following ocular surgery and CME; the potential of OCS-02 for treating DED; the potential of OCS-02 to become the first approved topical anti-TNFα for DED; the potential of OCS-05 for treating AON and other neuro-ophthalmic disorders; expected cash runway; expected future milestones and catalysts; the initiation, timing, progress and results of Oculis' clinical and preclinical studies; Oculis' research and development programs, regulatory and business strategy, future development plans, and management; Oculis' ability to advance product candidates into, and successfully complete, clinical trials; and the timing or likelihood of regulatory filings and approvals, are forward-looking. All forward-looking statements are based on estimates and assumptions that, while considered reasonable by Oculis and its management, are inherently uncertain and are inherently subject to risks, variability and contingencies, many of which are beyond Oculis' control. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those that we expected and/or those expressed or implied by such forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of Oculis, including those set forth in the Risk Factors section of Oculis' annual report on Form 20-F and any other documents filed with the U.S. Securities and Exchange Commission (the "SEC"). Copies of these documents are available on the SEC's website, www.sec.gov. Oculis undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.



    Primary Logo

    Get the next $OCS alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $OCS

    DatePrice TargetRatingAnalyst
    12/5/2023$30.00Buy
    Chardan Capital Markets
    10/5/2023$35.00Buy
    Stifel
    6/14/2023$22.00Buy
    BofA Securities
    6/12/2023$28.00Buy
    H.C. Wainwright
    6/8/2023$58.00Outperform
    Robert W. Baird
    5/10/2023$23.00Buy
    Pareto
    4/28/2023$27.00Outperform
    Wedbush
    More analyst ratings

    $OCS
    SEC Filings

    See more
    • SEC Form S-8 filed by Oculis Holding AG

      S-8 - Oculis Holding AG (0001953530) (Filer)

      6/5/25 4:38:25 PM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Oculis Holding AG

      6-K - Oculis Holding AG (0001953530) (Filer)

      6/5/25 4:05:17 PM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Oculis Holding AG

      6-K - Oculis Holding AG (0001953530) (Filer)

      5/9/25 4:10:10 PM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital Markets initiated coverage on Oculis Holding AG with a new price target

      Chardan Capital Markets initiated coverage of Oculis Holding AG with a rating of Buy and set a new price target of $30.00

      12/5/23 8:03:01 AM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on Oculis Holding AG with a new price target

      Stifel initiated coverage of Oculis Holding AG with a rating of Buy and set a new price target of $35.00

      10/5/23 7:50:21 AM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BofA Securities initiated coverage on Oculis Holding AG with a new price target

      BofA Securities initiated coverage of Oculis Holding AG with a rating of Buy and set a new price target of $22.00

      6/14/23 8:10:40 AM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

      ZUG, Switzerland, July 09, 2025 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to directors of the Company. Attachment Notification of managers' transaction - Riad Sherif - July 2025 RSU vest

      7/9/25 4:05:00 PM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oculis Publishes Results of 2025 Annual General Meeting

      ZUG, Switzerland, June 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis" or the "Company"), today announced the results from its 2025 Annual General Meeting held on June 4, 2025 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:00 p.m. CEST / 9:00 a.m. EDT. The Company's shareholders approved all agenda items. The shareholders approved the 2024 Annual Report including the 2024 Annual (Statutory) Financial Statements and the 2024 Consolidated Financial Statements. The shareholders acknowledged that on a standalone statutory financial statement basis, the Company incurred a loss of CHF 5,179,000 with respect to the financial year ended December 31, 2024, and

      6/5/25 4:00:00 AM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oculis to Participate in Upcoming June Investor Conferences

      ZUG, Switzerland, June 03, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that Oculis will be participating in the following upcoming investor conferences: Goldman Sachs Annual Healthcare ConferenceJune 9-11; Miami, FL, U.S.Fireside chat with Riad Sherif, MD, Chief Executive Officer, on June 10th from 9:20 to 9:55am ET. J.P. Morgan European Healthcare Conference June 12; London, U.K.Riad Sherif, MD, Chief Executive Officer, will be attending. The Company will be available for one-on-one meetings dur

      6/3/25 4:00:00 AM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCS
    Leadership Updates

    Live Leadership Updates

    See more
    • Oculis Publishes Invitation to the Annual General Meeting

      ZUG, Switzerland, May 09, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), today published the invitation to the 2025 Annual General Meeting, which will be held on June 4, 2025 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:00 p.m. CEST / 9:00 a.m. EDT. The 2025 Annual General Meeting will be held in-person and broadcast. To join the broadcast, please use the following link. Information pertaining to the 2025 Annual General Meeting, including meeting materials, can be accessed on the Oculis website here. Oculis will host a virtual information session for all shareholders on May 19, 2025 from 4:00 to 5:00 p.m. CEST / 10:00 to 11:00 a.m. EDT, during

      5/9/25 4:05:00 PM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

      Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today announces the appointment of Christina Ackermann as Chairwoman and Tim Ramdeen as a new member of its Board of Directors. Ms. Ackermann brings over 27 years of legal and management experience within the healthcare industries. Mr. Ramdeen has nearly a decade of experience in private equity, hedge fund investing, and capital markets. Christina Ackermann and Tim Ramdeen have led clinical and commercial companies through product development, growth, and commercialization while raising

      10/8/24 5:00:00 AM ET
      $ENTO
      $OCS
      $ONCO
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oculis Announces Appointment of Daniel S. Char as Chief Legal Officer

      Mr. Char brings extensive experience in leading legal, compliance and corporate governance functions in successful biotech and medical device companiesThe appointment further expands Oculis' leadership team as the company advances its late-stage pipeline and prepares for commercial phase ZUG, Switzerland, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the appointment of Daniel S. Char to the role of Chief Legal Officer, leading Oculis' legal, compliance and corporate governance functions. Mr. Char brings over 35 years of success in global legal leade

      10/2/24 4:00:00 AM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Oculis Holding AG

      SC 13G - Oculis Holding AG (0001953530) (Subject)

      12/9/24 9:43:55 PM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Oculis Holding AG

      SC 13G/A - Oculis Holding AG (0001953530) (Subject)

      11/7/24 4:15:49 PM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCS
    Financials

    Live finance-specific insights

    See more
    • Oculis Announces Positive Top Line Results from DIAMOND Stage 1 Phase 3 Trial in Diabetic Macular Edema with OCS-01 Eye Drops

      DIAMOND trial in Diabetic Macular Edema (DME) with topical OCS-01 met its stage 1 objective of validating the loading and maintenance dosing regimen designed to optimize OCS-01 efficacy potential with robust statistical significancePrimary efficacy endpoint of mean change in Best Corrected Visual Acuity (BCVA) versus baseline at Week 6 showed statistically significant increase in visual acuity in the OCS-01 arm compared to vehicle armStatistically significant secondary endpoints showed higher percentage of patients achieving ≥15-letter improvement in BCVA and better improvement in retinal thickness in the OCS-01 arm versus vehicle armOCS-01 was well-tolerated with no unexpected adverse event

      5/22/23 6:30:00 AM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oculis to Host Conference Call on April 13, 2023 to Discuss Late-Stage Pipeline and Near-Term Clinical Milestones

      ZUG, Switzerland and BOSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announces that it will host a virtual conference call and webcast to present an overview of its late-stage pipeline and discuss expected near-term clinical milestones on Thursday, April 13 from 8:00am-9:00am ET / 13:00-14:00 BST / 14:00-15:00 CET. Oculis is focused on becoming a leading global ophthalmic biopharmaceutical company with product candidates to address areas of significant medical needs, including diabetic macular edema (DME), dry eye disease (DED), and neuro-retina indica

      4/4/23 7:00:00 AM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care